Disclaimer: You are now leaving www.HIVReagentProgram.org and are going to a website that is not operated by NIH HIV Reagent Program. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE:
NIH HIV Reagent Program offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the NIH HIV Reagent Program website and will be redirected to another site. These sites are not under the control of NIH HIV Reagent Program.
NIH HIV Reagent Program is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Please read third party privacy and security policies closely as these may be different than NIH HIV Reagent Program policies.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
colder, preferably in the vapor phase of a liquid nitrogen freezer
Quantity limit per order for this item is 1. This item can be
ordered twice a year. Orders over this limit will be sent to NIAID for approval
ARP-1300 is a HeLa derivative that contains a stably integrated copies of fB, a rev-deficient human immunodeficiency virus 1 (HIV-1) HXB2 molecular clone.
The HLfB cell line was generated by cotransfection of HeLa cells with the plasmids fB and pSV2neo. Clone HLfB produces high levels of Gag and Env proteins only in the presence of Rev, and was selected in G418. The rev gene can be introduced into HLfB by transfection with a rev plasmid, by fusion to a rev-expressing cell line, or by fusion to Escherichia coli protoplasts containing bacterially-expressed Rev. High levels of virus are produced after introduction of Rev. Morphology is epithelial-like.
Growth Characteristics: Split cells twice weekly at a ratio of 1:10. HLfB cells are stable and do not need to be maintained in selection medium. If growth in selection medium is desired, propagation medium containing 500 µg per mL G418 should be used. The culture flask should be changed every two weeks. Avoid repeated passages of this cell line in culture because a gradual decrease in Env production occurs after the 15th passage. The available lot is passage #7.
Growth Medium: RPMI 1640 supplemented with 10% fetal bovine serum
ARP-1300 is negative for bacteria, fungi and Mycoplasma.
Each vial of ARP-1300 contains
approximately 4 × 106 cells in RPMI 1640 supplemented with 20% fetal bovine serum and 10% dimethyl sulfoxide (DMSO). Please refer to the
appropriate data sheet for lot-specific information.
Drysdale, C. M.
and G. N. Pavlakis. “Rapid Activation and Subsequent Downregulation of the
HIV-1 Promoter in the Presence of Tat: Possible Mechanisms Contributing to Latency.”
J. Virol. 65 (1991): 3044-3051.PubMed: 2033665.
Felber, B. K., C. M. Drysdale and G. N. Pavlakis. “Feedback
Regulation of Human Immunodeficiency Virus Type 1 Expression by the Rev
Protein.” J. Virol. 64 (1990): 3734-3741. PubMed: 2196381.
Felber, B. K.
and G. N. Pavlakis. “Cell Fusion and Transfection of HL3Ta and HeLa-tat Cell Lines.”
Courier 91 (1991): 8-10.
Hadzopoulou-Cladaras, M., et al. “The Rev
(Trs/Art) Protein of Human Immunodeficiency Virus Type 1 Affects Viral mRNA and
Protein Expression via a cis-Acting Sequence in the env Region.” J. Virol.
63 (1989): 1265-1274. PubMed: 2783738.
When applying for permits and forms please:
Do NOT reference NIH HIV Reagent Program or ATCC Catalog Numbers in the Material Description
fields found on the permits and/or forms.
Make sure your name and address on the permit applications and/or forms are exactly
as they appear on your NIH HIV Reagent Program registration.
Information about permits is provided as a courtesy to NIH HIV Reagent Program customers.
While we use reasonable efforts to include accurate and up-to-date information on
this page, we make no warranties or representation as to its accuracy.
For more information on the necessary compliance requirements associated with the
biological materials provided by NIH HIV Reagent Program, please select this link: Compliance Requirements.
Knowledge Base (FAQs)
Microsoft PowerPoint Viewer
Microsoft Word Viewer
Microsoft Excel Viewer
Call Us Toll-Free:+1 (888) 487-0727
TTY: (703) 365 - 2727